Jounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health Innovation Conference
Jounce Therapeutics (NASDAQ: JNCE) will have its CEO Richard Murray participate in a fireside chat at the Raymond James Human Health Innovation Conference on June 21, 2021, at 12:40 p.m. ET. This virtual event will be accessible via the company's website, where a replay will be available for 30 days. Jounce is focused on developing innovative cancer immunotherapies, including its lead programs JTX-8064 and vopratelimab, aimed at reprogramming tumor-associated macrophages and activating T cells, respectively.
- None.
- None.
CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Richard Murray, Ph.D., chief executive officer and president will participate in a fireside chat at the Raymond James Human Health Innovation Conference, taking place virtually on Monday, June 21, 2021 at 12:40 p.m. ET.
A webcast of the fireside chat will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be archived for 30 days following the presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, of JTX-8064 as a monotherapy and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, is currently enrolling patients with advanced solid tumors. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
Investor and Media Contacts:
Mark Yore
Jounce Therapeutics, Inc.
+1-857-200-1255
myore@jouncetx.com
Julie Seidel
Stern Investor Relations
+1-212-362-1200
Julie.Seidel@sternir.com
FAQ
What is Jounce Therapeutics participating in on June 21, 2021?
Who is the CEO of Jounce Therapeutics?
Where can I watch the Jounce Therapeutics fireside chat?
What are Jounce Therapeutics' main drug candidates?
How long will the replay of the Jounce fireside chat be available?
